TipRanks
Advertisement
Advertisement

KPRX Stock Latest News

Kiora Pharmaceuticals Bolsters Leadership in Clinical Development
Company AnnouncementsKiora Pharmaceuticals Bolsters Leadership in Clinical Development
28d ago
8K
KPRX
Kiora Pharmaceuticals: Global KIO-301 Partnerships and Advancing ABACUS-2 Study Support Buy Rating with Unchanged $12 Price Target
PremiumRatings
Kiora Pharmaceuticals: Global KIO-301 Partnerships and Advancing ABACUS-2 Study Support Buy Rating with Unchanged $12 Price Target
2M ago
KPRX
Kiora Licenses KIO-301 Rights in South Korea
PremiumCompany Announcements
Kiora Licenses KIO-301 Rights in South Korea
2M ago
8K
KPRX
Kiora Showcases Promising Preclinical Epilepsy Data for KIO-300
PremiumCompany Announcements
Kiora Showcases Promising Preclinical Epilepsy Data for KIO-300
4M ago
8K
KPRX
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
PremiumCompany Announcements
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
4M ago
8K
KPRX
Kiora Pharmaceuticals files to sell 11.8M shares of common stock for holders
PremiumThe FlyKiora Pharmaceuticals files to sell 11.8M shares of common stock for holders
5M ago
KPRX
KPRX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
KPRX Earnings this Week: How Will it Perform?
5M ago
KPRX
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
Premium
Ratings
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
6M ago
KPRX
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
PremiumCompany Announcements
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
6M ago
8K
KPRX
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
6M ago
8K
KPRX
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
PremiumRatings
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
7M ago
KPRX
Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
PremiumRatings
Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
11M ago
KPRX
Kiora Pharmaceuticals Reports Improved Financial Performance
PremiumCompany AnnouncementsKiora Pharmaceuticals Reports Improved Financial Performance
11M ago
KPRX
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
Premium
Company Announcements
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
11M ago
KPRX
Kiora Pharmaceuticals Advances Promising Eye Treatment with KIO-301 Study
Premium
Company Announcements
Kiora Pharmaceuticals Advances Promising Eye Treatment with KIO-301 Study
11M ago
KPRX
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?
PremiumCompany Announcements
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?
11M ago
KPRX
Kiora Pharmaceuticals files $100M mixed securities shelf
PremiumThe Fly
Kiora Pharmaceuticals files $100M mixed securities shelf
1y ago
KPRX
Kiora Pharmaceuticals Highlights at Ophthalmology Conference
PremiumCompany Announcements
Kiora Pharmaceuticals Highlights at Ophthalmology Conference
1y ago
8K
KPRX
Promising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals
PremiumRatings
Promising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals
1y ago
KPRX
Kiora Pharmaceuticals Advances Retinal Disease Pipeline
PremiumCompany AnnouncementsKiora Pharmaceuticals Advances Retinal Disease Pipeline
1y ago
KPRX
Positive Outlook for Kiora Pharmaceuticals: Buy Rating Affirmed Amid Promising Developments and Strategic Initiatives
Premium
Ratings
Positive Outlook for Kiora Pharmaceuticals: Buy Rating Affirmed Amid Promising Developments and Strategic Initiatives
1y ago
KPRX
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright
Premium
The Fly
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright
1y ago
KPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >